Altoida is at the forefront of developing innovative digital biomarkers aimed at enhancing the diagnosis and monitoring of neurological diseases, particularly Alzheimer's disease. Their approach leverages advanced technologies such as augmented reality (AR) and machine learning to create a tablet-based application that simulates activities of daily living. This application assesses cognitive and motor functions through a series of tasks designed to capture multimodal features, including micro-movements, reaction times, and navigation patterns. These features are then utilized to train machine learning models, referred to as Digital Neuro Signatures (DNS), which serve as objective indicators of cognitive performance.

The company's pioneering work includes a predictive machine learning algorithm that received FDA Breakthrough Device Designation in 2021, aimed at predicting the progression from Mild Cognitive Impairment (MCI) to Alzheimer's disease within a year. Altoida's mission is to facilitate early detection and assessment of cognitive impairments through efficient, real-time measurements, moving beyond traditional lengthy evaluations that often yield variable results. Their platform is currently intended for investigational use, with ongoing efforts to refine algorithms for diagnosing MCI and related conditions, ultimately aiming for FDA marketing authorization.

United States

Altoida is creating a new gold standard in brain health with Precision Neurology. We're radically transforming the method for measuring brain function and diagnosing neurological disease, using just your smartphone or tablet.

Our products are backed by more than 20 years of innovative research in digital biomarkers, augmented reality (AR), and artificial intelligence (AI).

Altoida received FDA Breakthrough Device Designation in July 2021. Our first device is a Computerized Cognitive Assessment Aid that is classified as Class II, 510(k) exempt.

Altoida

Company Details